Prime Medicine (PRME) Capital Expenditures (2021 - 2026)

Prime Medicine (PRME) has 5 years of Capital Expenditures data on file, last reported at $290000.0 in Q4 2025.

• Quarterly Capital Expenditures fell 72.2% year-over-year to $290000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 23.11% YoY) and the FY2025 annual result came in at $4.5 million, up 292.63% from the prior year.
• Capital Expenditures slipped to $290000.0 in Q4 2025, from $4.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q4 2023 to a low of -$10.3 million in Q4 2022.
• A 5-year average of $948941.2 and a median of $1.0 million in 2024 frame the typical range for Capital Expenditures.
• The widest YoY moves for Capital Expenditures: up 363.64% in 2024, down 1967.84% in 2024.
• Tracing PRME's Capital Expenditures over 5 years: stood at $754000.0 in 2021, then plunged by 1467.64% to -$10.3 million in 2022, then soared by 179.63% to $8.2 million in 2023, then plunged by 87.3% to $1.0 million in 2024, then slumped by 72.2% to $290000.0 in 2025.
• The last three Capital Expenditures figures came in at $290000.0 (Q4 2025), $4.1 million (Q3 2025), and -$2.3 million (Q2 2025), per Business Quant data.